Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GRF(1-44) research alliance

Aug. 30, 1996

Merck & Co. reports on L-163689

Aug. 30, 1996

Aldose reductase/5-lipoxygenase inhibitors reported by Tsumura

Aug. 30, 1996

Aldose reductase inhibitors from Terumo

Aug. 30, 1996

Sankyo reports novel hypoglycemic agents

Aug. 30, 1996

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Aug. 30, 1996

Beta3-adrenoceptor agonists described by Dainippon

Aug. 30, 1996

Cangene and Cheil Jedang sign Leucotropin agreement

Aug. 30, 1996

CCK antagonists from Warner-Lambert

Aug. 30, 1996

NGD-95-1 demonstrates safety in phase I

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...